| 영문 | cardiovascular system | 한글 | 심장혈관계 |
|---|---|---|---|
| 설명 | 신체의 혈액순환을 담당하는 기관. 즉 심장과 혈관을 통칭해서 이르는 말이다. |
||
| 영문 | autonomic nervous system | 한글 | 자율신경계 |
|---|---|---|---|
| 설명 | 사람의 의지와 관계없이, 침을 흘리거나 소화운동 등과 같은 스스로 조정이 되어 움직이는 신경계이며 여기에는 다음과 같은 두 가지가 있다. 1.교감신경계(sympathetic nervous system)-사람이 위험상태에 이르렀을 경우에 흥분이 되는 자율신경계. 즉 심박수의 증가, 소화기 운동의 감소 등의 일이 이곳을 통해서 일어난다. 교감신경이 흥분되면 교감신경의 말단에서 epinephrine, norepinephrine 등의 물질이 분비되고 이것들에 의해서 말초장기가 변화를 일으킨다. 하지만 장기에 따라서 epinephrine이나 norepinephrine의 수용체를 가지고 있어서 여러 가지 다른 장기의 반응을 볼 수가 있다. 수용체는 다음과 같다. -알파수용체(alpha-receptor): 말초혈관의 수축, 기관지의 수축, 동공의 근육의 수축 -베타1수용체(beta 1-receptor): 심장에 존재하는 수용체, 심장을 빨리 뛰게하는 역할을 한다. -베타2수용체(beta 2-receptor): 혈관의 이완, 기관지의 이완, 즉 각 장기들은 그 장기가 가지고 있는 교감신경의 수용체에 따라 교감신경의 흥분(교감신경 말단에서의 epinephrine의 분비)에 대한 반응이 달라진다(예-교감신경이 흥분시에 beta 1-수용체를 가지고 있는 심장은 빨리 뛰게 된다. 교감신경 흥분시에 동공의 근육이 수축해서 동공의 크기가 커진다) 2.부교감신경계(parasympathetic nervous system)-교감신경과 반대로 작용한다. 즉 사람이 졸리거나 쉴 경우에 흥분한다. 부교감신경이 흥분할 때에는 신경의 말단에서 아세칠콜린의 분비가 일어나고 이것으로 인해서 각 장기의 변화가 일어난다. |
||
| 영문 | TNM staging system | 한글 | 종양병기분류계통 |
|---|---|---|---|
| 설명 | 종양의 병기(stage)를 결정하는 한 방법. T는 Tumor(종양)를 뜻하며 원발병터의 크기, 주위조직으로의 침윤정도 등에 따라 T1, T2, T3, T4(숫자가 높을 수록 주위로 침윤이 많다) 등으로 나눈다. N은 Node(림프절)를 뜻하며 침범된 림프절의 갯수, 크기, 위치 등에 따라 N1, N2, N3 등으로 나눈다. M은 Metastasis(전이)를 뜻하며 원격전이의 유무에 따라 M0, M1 등으로 나눈다. 이상의 방법으로 T, N, M이 결정되면 이들을 조합하여 최종적인 병기를 결정한다. 이렇게 결정된 병기는 치료 방침 결정과 예후 판단에 매우 중요하다. |
||
| 영문 | central nervous system(CNS) | 한글 | 중추신경계 |
|---|---|---|---|
| 설명 | 신경계는 중추신경계와 말초신경계로 분류할 수가 있다. 중추신경계란 뇌와 척수로 구성되어 있는 신경계를 이르는 말이다. 말초신경계란 이 이외의 모든 신경계를 이르는 말이다. |
||
| short-FRAME | short stature-facial anomalies-Rieger anomaly-midline anomalies-enamel defects [syndrome] |
|---|---|
| VACTERL | vertebral abnormalities, anal atresia, cardiac abnormalities, tracheoesophageal fistula and/or esoph... |
| VATER | vertebral defects, imperforate anus, tracheoesophageal fistula, and radial and renal dysplasia |
| ZD | zero defects; zero discharge; zinc deficiency |
| ECG | Electro-Cardio-Graphy(-Gram); 심전도 = EKG 1. Conducting System Structu... |
| complement cytolysis inhibitor | <protein> Vertebrate glycoprotein of uncertain function. Secreted as a 400 amino acid peptide, then cleaved to form two 200 amino acid peptides that are linked by a disulphide bridge. Synonym: complement associated protein, complement cytolysis inhibitor, glycoprotein III. (11 Jan 1998) |
|---|---|
| complement factor h | <chemical> A beta-globulin that binds to complement 3b and makes ic3b (inactivated complement 3b) susceptible to cleavage by complement factor I. Complement factor h also acts as an alternative pathway complement inhibitor by interfering with the binding of properdin factor b to c3b. Chemical name: Complement factor H (12 Dec 1998) |
| complement factor I | <enzyme> Serine proteinase that acts on ic3b (inactivated complement 3b) to cleave it into c3c and c3dg with the help of a trypsin-like proteolytic enzyme. Complement factor I was formerly called kaf, c3binf, or enzyme 3b inactivator. Registry number: EC 3.4.21.45 (12 Dec 1998) |
| complement fixation | <immunology> Binding of complement as a result of its interaction with immune complexes (the classical pathway) or particular surfaces (alternative pathway). (18 Nov 1997) |
| complement-fixation reaction | <immunology> Binding of complement as a result of its interaction with immune complexes (the classical pathway) or particular surfaces (alternative pathway). (18 Nov 1997) |
| complement-fixation test | An immunological test for determining the presence of a particular antigen or antibody when one of the two is known to be present, based on the fact that complement is "fixed" in the presence of antigen and its specific antibody. See: Bordet-Gengou phenomenon. (05 Mar 2000) |
| complement fixation tests | Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualised by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (haemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1. (12 Dec 1998) |
| complement-fixing antibody | Antibody that combines with and sensitises antigen leading to the activation of complement, which may result in cell lysis. Synonym: CF antibody, sensitizing substance. (05 Mar 2000) |
| complement haemolytic activity assay | Usual screening assay for complement. Dilutions of the serum to be tested are added to antibody-coated erythrocytes and the percentage of lysis is measured. The values are expressed by ch50, haemolytic complement units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay. (12 Dec 1998) |
| complement inactivators | Serum proteins which act at key sites in the complement sequence to modulate or prevent the progression of the reaction. Absence of these factors leads to uncontrolled activation of the complement system with accompanying disease. (12 Dec 1998) |
| complement membrane attack complex | The assembly of complement plasma glycoproteins c5b, c6, c7, c8, and polymeric c9 as a group on biological membranes. The complex forms transmembrane channels which displace lipid molecules and other constituents, thus disrupting the phospholipid bilayer of target cells leading to cell lysis by osmotic leakage. The formation of the membrane attack complex is the terminal step in the complement cascade. (12 Dec 1998) |
| complement pathway, alternative | The complement activation sequence initiated by the activation of complement factor c3, which is triggered by the interaction of microbial polysaccharides and properdin without participation of an antigen-antibody reaction. (12 Dec 1998) |
| complement pathway, classical | The sequential activation of complement, initiated by antigen-antibody complex and the binding of complement factor c1q to the fc region of the antibody. (12 Dec 1998) |
| complement unit | The smallest amount (highest dilution) of complement that will cause haemolysis of a unit of red blood cells in the presence of a haemolysin unit. Synonym: alexin unit. (05 Mar 2000) |
| component of complement | Any one of the nine distinct protein units (designated C1 through C9 and distributed in the a, b, and g electrophoretic partitions of normal serum) that effect the immunological activities long associated with complement. C1 is a complex of three subunits: C1q, C1r, and C1s. C1q (overbar indicates "active form") activates proenzyme C1r to C1r which activates C1s to C1s (also known as C1 esterase), which converts proenzyme C2 to C2b and produces C4b from C4. C2b combines with C4b to form "classical-complement-pathway C3/C5 convertase" (also known as C3 convertase, C5 convertase, and C42). This enzyme cleaves C3 to C3a and C3b, and C5 to yield C5a and C5b, as does "alternative-complement-pathway C3/C5 convertase" (also known as proenzyme factor B, properdin factor B, C3 proactivator, and heat-labile factor). Complement factor I (also known as C3b or C3b/C4b inactivator) inactivates C3b and C4b by a different proteolytic cleavage. Several autosomal recessive disorders have been identified in which one or more of the complement components have been deficient or completely absent. (05 Mar 2000) |